CAMBRIDGE, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- Biogen (Nasdaq:BIIB) today announced it will host a live webcast providing a Q&A session related to its Alzheimer’s disease investigational therapies on Wednesday, July 25, 2018. The live webcast will begin at 6:00 p.m. ET/5:00 p.m. CT on July 25, 2018, with Alfred Sandrock, Jr., M.D., Ph.D., executive vice president and chief medical officer at Biogen, and Samantha Budd Haeberlein, Ph.D., vice president, Alzheimer’s disease, dementia and movement disorders, late stage clinical development at Biogen. To access the live webcast, please go to the Investors section of Biogen’s website at www.biogen.com/investors. Following the live webcast, an archived version of the call will be available on the website.
Biogen’s webcast follows its presentations on aducanumab and BIIB092 as well as its partner Eisai’s presentations on BAN2401 and elenbecestat at the 2018 Alzheimer’s Association International Conference (AAIC). The BAN2401 Study 201 data presentation will also be webcast live. To access that live webcast, please visit the Investors section of Eisai's website on July 25th at 4:30 p.m. ET/3:30 p.m. CT at https://www.eisai.com/ir/index.html.